Comment: What science says about vaccines and a fourth shot

Some will likely need a second booster, but most remaing protected against severe covid disease.

By Monica Gandhi / Special To The Washington Post

Pressure is building to approve a fourth dose of the coronavirus vaccine in the United States, which is facing another potential wave of infections.

Already, the two major vaccine makers have asked the Food and Drug Administration to sign off on another booster shot, recognizing that the vaccines’ effectiveness wanes over time. All this talk has raised a depressing possibility: Will we all have to keep getting shots every few months forever into the future?

The answer, thankfully, appears to be no. The evidence suggests that most people won’t need a fourth dose. Immunocompromised people and the elderly, who are at risk of severe breakthrough infections, will probably need another shot; and may need to keep getting them until a more long-lasting vaccine is made available. But for most people, the immunity conferred by the first round of vaccines and natural infection will be enough to keep us safe.

How can we be sure? We know that the vaccines generate antibodies against SARS-CoV-2, the virus that causes covid-19, but that these antibodies can be less effective against new variants like omicron. Even if those antibodies are boosted with an extra shot, their effectiveness will wane several months later. Luckily, the vaccines also generate something called cellular immunity, which is longer-lasting, and protect against severe disease in a more enduring fashion.

Antibody-producing memory B cells — generated by the vaccines or as a result of a prior infection — have been shown to recognize the virus, including its variants. Although we do not know how long these memory B cells last, survivors of the 1918 influenza pandemic were able to produce antibodies from memory B cells when their blood was exposed to the same strain nine decades later. The vaccines also trigger the production of T cells.

While B cells serve as memory banks to produce antibodies when needed, T cells amplify the body’s response to a virus and help recruit cells to attack the pathogen directly. Memory T cells generated by covid-19 infection may last a lifetime, according to a study that examined participants with varying degrees of initial disease severity. Memory T cells generated in individuals who survived a different coronavirus infection in 2003 were shown in a recent paper to last at least 17 years.

During the omicron variant surge this winter, we did see a greater chance of re-infection compared with previous variants; but not in severe disease across the general population. A study from Qatar showed that a history of natural infection protected against mild re-infection with previous variants 90 percent of the time, but that protection declined to 56 percent against omicron. Two vaccines protected against mild re-infection 89 percent of the time against the delta variant, but that protection declined to 36 percent against omicron in a Canadian study. This is probably because the omicron variant was able to evade antibodies. In both studies, however, protection against severe disease endured, probably mediated by cellular immunity.

The increase in antibodies from a vaccine boost may last only a short period, around four months, according to one study by the Centers for Disease Control and Prevention. But this boost will be necessary for certain groups to maintain protection against severe disease, including the immunocompromised, older people and those with multiple risk factors. This is because B cells typically take two to four days to make neutralizing antibodies, which may be too long to wait for those who are more susceptible to severe disease. In another recent CDC study, those who were severely immunocompromised (for instance, patients on B cell-depleting therapies or solid organ transplant recipients) and those older than 75 with four comorbidities were found to be susceptible to severe breakthrough infections. Immunocompromised individuals have already been approved for a fourth shot, and those who are older with other medical conditions should obviously be next in line.

But there is little evidence that a fourth shot would be beneficial for the rest of the U.S. population. A recent study in the New England Journal of Medicine showed that a fourth shot in health care workers did not improve the effectiveness of the vaccine or reduce viral loads.

In the future, instead of using an mRNA or DNA vaccine that exposes us only to part of the virus (the spike protein, which is mutated across all the variants), we may need a vaccine booster that exposes us to the entire virus. Whole virus vaccines may be more protective against variants with multiple mutations in the spike protein. Vaccines given inside the nose can help boost antibodies at nasal surfaces, which will help with curbing viral transmission.

For now, the vaccines we have are doing a good job of preventing severe illness in most people. Vulnerable people should start getting a fourth shot to shore up their defenses. For everyone else, though, it makes little sense to give more booster shots.

Monica Gandhi, an infectious-diseases specialist, is a professor of medicine at the University of California, San Francisco.

Talk to us

> Give us your news tips.

> Send us a letter to the editor.

> More Herald contact information.

More in Opinion

toon
Editorial cartoons for Thursday, Feb. 13

A sketchy look at the news of the day.… Continue reading

People walk adjacent to the border with Canada at the Peace Arch in Peace Arch Historical State Park, where cars behind wait to enter Canada at the border crossing Monday, Aug. 9, 2021, in Blaine, Wash. Canada lifted its prohibition on Americans crossing the border to shop, vacation or visit, but America kept similar restrictions in place, part of a bumpy return to normalcy from coronavirus travel bans. (AP Photo/Elaine Thompson)
Editorial: U.S. and Canada better neighbors than housemates

President Trump may be serious about annexing Canada, but it’s a deal fraught with complexities for all.

State single-payer health care bill offers many advantages

I was excited to read in Will Geschke’s report (“Everett lawmakers back… Continue reading

Important national story missing from Herald

I couldn’t find a report in The Herald that the Trump administration… Continue reading

Comment: Trump’s ‘Man-of-Steel’ shtick will make U.S. weaker

Trump’s 25 percent tariffs on steel and aluminum will harm allies we need and won’t help industries here.

Comment: AG Bondi’s DEI memo more messaging than lawsuit threat

Talk of criminal investigations is intended to panic corporations into abandoning their DEI programs.

Goldberg: Why Musk, Vance went to bat for self-desribed racist

While a former Trump official is on the outs for doing his job, a proud racist gets his job back.

toon
Editorial cartoons for Wednesday, Feb. 12

A sketchy look at the news of the day.… Continue reading

CNA Nina Prigodich, right, goes through restorative exercises with long term care patient Betty Long, 86, at Nightingale's View Ridge Care Center on Friday, Feb. 10, 2023 in Everett, Washington. (Olivia Vanni / The Herald)
Editorial: Boost state Medicaid funding for long-term care

With more in need of skilled nursing and assisted-living services, funding must keep up to retain staff.

Welch: State Democrats’ bill would undermine parental rights

The bill would allow kids as young as 13 to make mental health decisions without notice to parents.

Kristof: Child malnutrition lost in politics over aid cuts

A young journalist describes the scene in Madagascar where a nutritious porridge provides a lifeline.

Comment: Trump sticks with NOAA official who bent to his ego

We haven’t seen the last of Trump’s Sharpie-amended reality and it’s destabilizing effect on scientists.

Support local journalism

If you value local news, make a gift now to support the trusted journalism you get in The Daily Herald. Donations processed in this system are not tax deductible.